transcribe

DeepSeek’s V4 Coding Leap, Strava’s IPO Move & Silicon Valley’s Aging Craze | Jan 9, 2026

The Information · 51m · transcribed 3d ago
More from The Information Business
𝕏 Share ▶ YouTube 📥 PDF 🤖 .md

Section Insights

# 0:00

Introduction and Upcoming AI Model Launch

What are the key topics and guests for today's show?

The show will cover the upcoming launch of DeepS's new AI model, an IPO filing by Straa, and Lambda's fundraising efforts. Guests include Dan Shipper from EveryY and Zach Rayano from Row.

  • DeepS is launching a new AI model called V4 soon.
  • Straa has filed confidentially for an IPO.
  • Lambda is raising $350 million ahead of its IPO.
# 10:15

M&A Conversations and Lambda's IPO Plans

What is the current status of M&A discussions and Lambda's IPO?

There are no explicit M&A conversations, but larger companies may consider acquiring smaller firms like Lambda, which is trying to raise $350 million before going public.

  • Larger companies like Apple and Garmin could be potential acquirers.
  • Lambda is seeking significant funding to support its IPO.
  • The performance of Lambda post-IPO will be closely watched.
# 20:30

AI's Impact on Non-Coding Applications

How is AI changing the way we interact with technology?

AI is extending its capabilities beyond coding, allowing for more valuable interactions, such as automating routine tasks in web settings.

  • AI can significantly reduce the time spent on routine tasks.
  • The integration of AI into daily workflows can be transformative.
  • Users are beginning to experience life-changing benefits from AI applications.
# 30:45

Enhancing Patient Experience with LLMs

How are LLMs improving patient response times for side effects?

LLMs are enabling faster and more efficient processing of unstructured data related to patient side effects, reducing response times significantly.

  • LLMs have reduced side effect response times from hours to minutes.
  • The ability to structure unstructured data is a game changer in healthcare.
  • This technology enhances the overall patient experience.
# 41:01

E-commerce Innovations and Skepticism

What are the implications of new e-commerce features announced by companies?

Companies are introducing new features for in-window shopping, but skepticism remains about their effectiveness and scalability.

  • New shopping features aim to improve conversion rates by keeping users on the same page.
  • Many announcements may not lead to successful implementations.
  • Skepticism is warranted as the effectiveness of these innovations is yet to be proven.

Transcript

0:13 Welcome everyone to the information's ti. My name is Akash Pasicha. It is Friday, January 9th. We have a busy show to close out the week. First up, the information published exclusive reporting that DeepS is just weeks away from releasing its new flagship AI model. We will discuss the news with our Asia bureau chief. We're also exclusively reporting that Straa has filed confidentially for an IPO. And Nvidia backed cloud provider Lambda is in talks to raise $350 million ahead of its IPO. We will break down both of those stories. We have a great lineup of guests for you. Dan Shipper, CEO at EveryY, will join the program to talk AI and media. And we are also sitting down with Zach Rayano, CEO of Row, who will talk about the company's new GLP1 pill launched with Novo Nordisk. And it is Friday, so it's time for another edition of the editor's cut. And our weekend reporter will wrap the show talking about Silicon Valley's latest obsession, learning your biological age. It is a jam-packed show and so let's get right on into things. The information published exclusive reporting that DeepS is expected to launch its nextG AI model in the coming weeks. Joining me now with the details is our Asia bureau chief Jen Yang. Jen, welcome back to the show.

1:32 It's great to have you here. >> Thank you, Aash. Glad to be back in a new year. First, >> so what what do we know about this new model and the Deep Seek news? >> Yeah. So the new model is going to be called V4 which is a successor to V3 which was launched in December 2024 and this new model features very strong coding capabilities. DeepSeek employees conducted testings based on their own internal benchmark and those testing showed that V4 outperforms both you know anthropic and open models in coding. Obviously, the the proof is going to be in the pudding. We won't know if it really outperforms until, you know, we see what it is.

2:20 >> Well, I mean, the first step is getting it out there. So, that's that's the the the first step here. Talk to me about what is the difference between the the V series models and then the R1 model that I know has gotten a lot of attention at Deepseek. >> Yeah. So VC wave 3 was launched in December 24 as I mentioned that model was already very good. It's a large language model, general purpose model what we call that you know already put the company on the map of the global a in the global AI community and the R1 the R series which only had one generation so far is what we call a a reasoning model basically it can perform like it takes time to think and then perform a series of tasks in a logical se sequence and that was the model by the way which was released in January 205 about a year ago. ago that you know shocked that sent shock waves from Silicon Valley to Wall Street. that was what we now call the Deep Seek moment.

3:23 >> Okay. I wonder how you think about Deep Seek's model releases in the context of its position in the AI race. Is it in a similar sort of arms race as we see here in North America with respect to just trying to get the best model? I mean is it working on anything broader than the models and applications that people can use? so Deepseek as you know is like a big champion for open source and then all of their models have been open source and when R1 was after VC V3 and excuse me after W3 and R1's releases it sort of started in China this intensified competition and then really like raised the awareness of open source among the Chinese a developer community and throughout 2025 we see companies from you know giants like Alibaba and BYU to startups like Japool, Mini Max and Moonshot all rushed raced to release their own open-source model offerings. and however in the same time you know DeepS simply you know sort of has gone quiet. you know if they do release V4 like we write about in the next few weeks around mid midFebruary that will be the their first major model release after they became a global sensation. And then in the US as we know llama developed by mata was you know a big champion is a big champion of open source where I think most of the other model developers in the US sort of have taken the closed source approach and then the deepseek moment last year also sort of incentivized some discussions over you know if we actually should in the US if we should actually you know do more open source models as Well and right now we we haven't seen that really happening at a larger scale.

5:28 and then DeepSeek plus you know the other Chinese model developers that have taken the open source route following DeepS's lead has in the past year really sort of make China Chinese open source model really the most used by number of tokens around the world when it comes just you know open source models on their own. Great. Well, it is a story that we are following closely. Jing, I want to thank you for coming on. That is Jing Yang, our Asia bureau chief here at the information.

6:02 Okay. Straa has filed confidentially to go public. That is according to a new exclusive story from the information. I want to bring on our deputy bureau chief of finance, Corey Weinberg, to talk about the state of that business. Corey, welcome back to the show. It's great to have you here. >> Hey, Akos. Good morning. Is that the LA light that I got you for Christmas behind you? >> Yeah, I mean it is a I I loved it. And to to bring our listeners and viewers up to speed, the information does have a a secret Santa celebration internally and I guess Akos was was mine. I was very thoughtful that the LA Dodgers won this year and I was also a little upset because of course they beat my beloved Blue Jays, but I'm a good sport and so are you. You put it up. So, thanks for doing that. I appreciate it.

6:56 >> >> absolutely. The good signpost for LA. >> All right, so let's talk about Strama, which maybe you're a power user, maybe you're not. Maybe we'll get there. I don't know. But you reported that the company has filed confidentially to go public. This is a business that we have been writing about for a little while at the information. What do we know about the state of that business? >> Yes, I think Straa's going to surprise people when it S1 comes out in a couple months. the business has been has had one of those unusual stories where it's it's been around forever. you know, this company have was founded, you know, when I was was still in high school, so so quite quite a while ago. and you know, it it has picked up growth as of late. So, its revenue is between four and $500 million was what we learned.

7:53 but it's growing really quickly. It's growing over 50% a year, which would make it the fastest growing or or one of the fastest growing consumer apps on the public markets should it should it go public. So, that should be interesting to to at least some investors. >> I guess it's kind of interesting with consumer apps. I mean 50% growth is staggering for any company but I guess the risk with consumer is that if it's if it's in it's in and you know you could have a good year but then if it falls out of favor then we don't know what's going to happen.

8:24 >> Yeah that's exactly I mean that's how I would think about the the bear case as well. I mean we'll see once we actually see full more fully what the numbers in the story look like but yeah it could be a fad right now but right now it's in and you know there are run clubs all over the place. I, you know, I just moved to LA. Maybe I'll join join a run club. but but, you know, it has like a decent sort of, it's in with the fads right now. People like running.

8:51 that's helped it grow beyond just cycling, which was kind of its original use case. so, but you're right, like it it could become not trendy very Who do you think would be a good public comp for Strava out there? I think the one that I've heard is Dual Lingo. just in terms of subscription business for you know that that is sort of making money off of people's you know sort of hobbies or or side quests so to speak.

9:23 so that that's one that's sort of come up in my reporting so far and I think Martin our colleague shouted that out last night as well. Well, and so one of the other things I've been thinking about is you talked in the story about you know how sorry getting a we got some noises here in the office folks but we're still we're still we're still going on with things. U you u you had this piece in the story about you know the the company being profitable. and we also wrote a weekend profile about the company a little while ago. And look, I mean, this is a business that I could have seen getting acquired potentially a couple years ago just given the product suite that it has.

10:06 is this all just financial discipline that it's been able to acquire other businesses or what do you chock that up to? >> Yeah. we don't know much about sort of whether there's been explicit M&A conversations. Obviously, you know, fit large. There are larger companies that care about fitness that you would think and health that you would think would be logical acquirers, Apple, Garmin, you know, you've obviously seen private companies like Aura, and you wrote about Whoop, you know, sort of, take off on more of the hardware side.

10:40 So, I don't know. I mean, I think it's logical to say this company is still pretty small. We we called that out in the story. you know, that that revenue, that topline revenue between four and 500 million, that that's that's not huge for a public company. but yeah, we'll see. We'll see how it trades after it goes public. If it doesn't do well, I think it'll definitely get bought. >> Okay. So, let's talk about another story that you published this week. You reported that you had some new reporting about Lambda, the Neocloud company. Tell us about what you learned there.

11:10 >> Oh, Neocloud. It's getting interesting. About this time last year, we were all gearing up for the core or maybe not all of us, but I was gearing up for the core IPO, which which happened in March last year. Lambda is is a bit seemingly it's its little cousin. it has a very similar business in in that they're trying to become some of the next big cloud providers, but their key tenpole is access to Nvidia chips. Nvidia is both an investor and a customer which is a similar dynamic to Coreeave. and they're trying to go public. These businesses need a ton of cash. They have debt. and before it goes public, what we wrote yesterday is it's trying to raise at least $350 million in what's known as a preIPO convert a convertible note. and so that, you know, we think is interesting and you know, definitely previews an IPO. I I gotta be honest, Corey, it's kind of funny. You are you you are seemingly the only person I know that gets more excited about the Neocloud sector than about Straa. I I thought Strava was the more interesting business, but I guess Neoclouds are like I mean, you know, they are very much in this moment.

12:24 >> Hard they're harder, you know, to unpack or they're they're they're more controversial maybe like Strava is it is what it is. I don't know. It's a good sub app that people use and it bakes money. Neoclouds always generate a lot more conversation because people don't don't know what to make of them. They they are more interesting and weirder kind of financial animals. like I said, they have debt. They're they all grow really fast. you know, Lambda's growing sales about 80%.

12:55 but I think the question with them is like what what's their IP? What is this company? you know, sort of does it have a lasting business strategy beyond just being able to capture the AI boom. Now, you had this line in the story that I want to read. you said the terms of the new financing would pressure the company to list publicly the deal, which is structured as convertible notes, would force Lambda to award participating investors millions of dollars of additional equity or cash interest payments if it doesn't go public within a year. it. I I want you to explain that a little bit to us and broadly the point I'm trying to get at is you know these complexities in deal terms. I mean is that becoming more common in this moment in AI? Talk a little bit about that. It it predates that a bit. I would would take it back about a decade now. it really these kind of preipo you know structured rounds became much more popular when there became kind of a a bigger rush of capital into the private markets there became a deeper pool of investors that were interested in getting a piece of companies before they went public you know and and a an instrument a financial instrument like this it's designed to protect investors potential downside as well as giving them a piece of, you know, a potential upside rocket ship and they're meant to, you know, they're designed to be raised fairly quickly and and so that it removes some of the haggling over something like a valuation.

14:32 >> Great. Well, Corey, I want to thank you for coming on. That is Corey Weinberg, our deputy bureau chief of finance here at the information. Okay. AI has seated a whole new generation of entrepreneurs that are finding ways to reinvent old business models and also rethink how we use everyday applications. Dan Shipper is one of those entrepreneurs. His company, Every is part media company, part AI app company. I want to bring him on to talk more about the future of his business.

15:00 Dan, welcome to the show. It's great to have you here. >> Thanks for having me. It's great to be here. >> Tell us about everything that every is because there's a lot going on over there. There is a lot going on. You can think about it in a very simple way. We think about every as the only subscription you need to stay at the edge of AI. And we have three main pillars of the business. One is ideas, two is apps, and three is training. On the ideas side, we have a daily newsletter about AI. We do vibe checks.

15:28 So, you know, when a new model comes out, for example, we'll get our hands on that model before it comes out and we'll do a hands-on review of it the day it comes out. We have a lot of stuff like that in our newsletter. We have a podcast. That's that's the sort of idea side. then we have an apps side of the business where we have four AI apps that we build and run internally. Each is run by a single engineer. one's called Kora. It helps you manage your email with AI. One's called Monologue.

15:52 It's a smart dictation app. One's called Sparkle. It's a AI based file manager. And one's called Spiral. It's an agentic ghost writer. so that's the app side of the business. It's all tools that we build for ourselves to work better on the edge of AI. that we also give to our subscribers. And the last part of the business is training. So for people who want to go deeper than just using our tools or reading our writing. we actually do hands-on trainings. We do what we call camps where we for subscribers they do we have live streams where they can see how we use cloud code for example or you know next week we're we're having the cursor team on to come talk about how to use cursor really well for for AI coding in an enterprise environment. All that kind of stuff. So we have camps and we have an enterprise offering where big companies we have an enterprise offering where big companies bring us in to actually train their people and we bundle this all together in one subscription >> and with the apps I'm curious is the goal here to compete with and I'm thinking about email here because email is one where you've got these massive platforms is it literally competing with these with these AI email clients you know I'm thinking of you know the superhumans stuff like that or is Is it a more niche offering?

17:04 >> I like eventually yes I think it'll it'll compete with you know when I think about the the giants it's like competing with Google or Gmail like that kind of thing. for now it works with Gmail it works with superhuman. and over time we're adding adding more and more functionality. I think the the the market that we're going after is really high AI early adopters who want to use features at the edge. And those are people that a company with a much bigger audience can't serve right now.

17:34 And it's actually quite a small market, but I think it'll be the biggest market in the world in 10 years. And we're really really focused on those people who want to use an agent like in their email for everything that they do. and and that's where we're starting which I think is very different from a superhuman or a Gmail where they have to sort of split the difference between AI early adopters and everybody else. Now, agents is kind of an interesting area right now because I I look at my own use of AI and I I certainly use it, but I I don't know that I use as many agents as maybe I could be or should be. And you sit at this interesting junction of, you know, trying to convince people to use these agents and and embedding that into your apps. I wonder what reflections you've had from building in this space about how you can convince people to use agents because it's a bit of a behavioral leap and you know I I don't know how you think about incentivizing that you know it's it's ultimately about trust. It's about having an experience where you use an agent for the first time and you're like oh my god I cannot believe that actually worked. And everybody has moments like that. And and I think our job as people who make software and also people who write a lot is to help people get to that faster.

18:52 And and make sure it's clear like what the value is. Like it's it's no it's not interesting to use an agent just to say, "Hey, I'm using an agent." I think in 2025 toward right towards the end of 2025 is when programmers really began to be like, "Oh, wow. Agents are completely changing my entire workflow." agents really started there. you know, you can use cloud code for like 20 or it'll go off and code for 20 or 30 minutes or codeex can go off for hours. and that is really changing programming and it it has not quite gotten to that level for the rest of knowledge work. But I think 2026 is when we're going to see that happen. And the reason for that is all of these coding agents that are built specifically for coding actually translate very well into general purpose agents. And so they're becoming the foundation for general purpose agents that nontechnical people are going to be using in 2026 and 2027 and beyond.

19:43 >> So if I'm hearing you correctly, you're saying that the key to trust is having a product that that works extraordinarily well. And until now, we haven't really seen the models be good enough, but in 2026, you see them finally crossing that that mark. >> Yeah, you can think of models as like having a having a leash. And I think you know when AI when GP3 for example which is the first like real consumer application of LMS when CHBT came out when we started using GP3 it was the leash is very short it's like one prompt one response and the response comes really quick and over time that leash has gotten longer and longer and it's the longest right now in in coding applications and and the leash is only allowed to get longer when the AI is going to reliably do something valuable with that extra time. if it's not going to do something valuable, it's not worth the time. And I think what we're going to find over the next year or so is that leash for non-coding applications is going to get a lot longer because there's going to be a massive amount of value that you see allowing it to go off and do something. And a a specific example that I can give you that I experience all the time which maybe people who are watching this are not yet experiencing is I use an agentic browser. So I use chatgbt atlas. It's from openai and anytime I have to change a setting on a website for example I don't have to deal with that and I get asked that. I get asked for that all the time because I you know I run a company we have 20 people. I'm always asked like can we invite someone to this or can you change the security se setting on this app and my browser just now does that for me. So, I never have to look at a settings panel ever anymore. And that's one of those things where it's a it can be a light bulb moment for you to be like, "Oh my god, this is life-changing."

21:31 >> You also are running a media company, which in the era of AI is kind of interesting. And you do some some great writing on your website. What have you learned about running a media company in this era that you might not have expected when you started out on this project? >> That's a great question. yeah, I I I think of everything as being tightly integrated. It's ideas, apps, and training. And you know, if you want to teach people how to like really live at the edge of AI, you need to do three things. You need to spread the word, and that's the media part of what we do and the stories that we tell. You need to give them tools to use, and and we give them tools that we use ourselves, and then you have to get hands-on with them to like teach them for people who want to go deeper.

22:13 And I think obviously media is a critical part of that, but also there's this really interesting thing happening where there's not a clear bifurcation between a media company and a software company anymore. because you can now program using English, the line between writer and builder is starting to blur. And so everybody internally at every is both a writer and a builder. >> So everyone who's writing an article is also contributing to building these these apps. >> Yeah. because you can just vibe code, you know, your own product.

22:46 >> Exactly. And vice versa. and so, so that's a big deal. But also another big interesting part of this is that because software is so cheap to make now, it actually has a lot of the same properties like building a new app has a lot of the same properties as writing essay or making a video. you can think of software as a form of content now. And so the the that's that's another reason why the software part of things is not separate from the media part of things because for us if a new model comes out we can go vibe code a new app to display its capabilities and then launch the app and that's the equivalent of writing a really cool article about it because we're showing people hey we built this thing and it's not an app that we necessarily are going to support. It's just like a demonstration of what's possible now and I think that's really interesting.

23:32 >> Great. Well Dan I want to thank you for coming on. That is Dan Shipper, co-founder and CEO of Every here on TIV. Okay, if you live in New York, you might have seen the Subway ads of Serena Williams injecting herself with GLP1s. The company behind that ad is health tech company Row. And this week, it announced it is now offering the new Wikovi pill from Novo Nordisk. I want to bring on Zack Rayano, the co-founder and CEO of Row to talk about his business.

24:00 Zack, welcome to the show. It's great to have you here. Thanks for having me. >> So, this is the pill that you can take. This is not we're we're we're done with injectables or or or those going away. >> We're done. I think this is a Yes. And this is really exciting. That's right. That's right. >> But but I mean long term I mean the injectables they probably go away, right? >> I think it'll depend on the individual and and the main reason is so the the amazing thing for us to talk about the pill is I I do think that it is going to usher in a new era of digital health, right? Direct to consumer health. It's the first time a drug of this size and scale launches nationwide on row. So someone can see an ad and go from diagnosis to delivery in 48 hours or less. And the cool part about this pill in particular right now is one, it's more affordable. So it's $149 to start, but two, to your point, patients don't have to trade off between efficacy and the preferred form factor for many. So patients on treatment saw about 16 to 17% weight loss on the pill. That's going to be transformative. So it's a better form factor for many. It's more affordable and it's available today on row. The the thing that you mentioned though about injectables is you do see both current injectables. There are some where patients lose 20 22% and there are GLP ones in the pipeline. Maybe people have heard of in Silicon Valley maybe they've heard of triple G or Redat or Kagma. There are others that are coming out in 26 27 28 and beyond where patients are losing 25 30% of their weight. And so you will usually see the the pills be slightly less effective over in the fullness of time. So it really depends.

25:37 >> What what about side effects? Is there any difference in terms of side effects? >> They're quite comparable. They're quite comparable. the pill and the injectable. Yeah. >> And generally speaking, I mean side effects are I mean where are we in that story of people seeing u any kind of adverse effects here? >> Yeah. The the typical ones that people see are you know nausea, gastro challenges and issues. and and there in terms of the frequency, you know, over in the clinical trials, you know, it might be 30 40% of people, but they the side effects and it depends how wonky we want to get. They usually people they subside over time.

26:12 they're usually what referred to as peak to trough side effects. So it's when people start or they escalate in dose, but people can and there are ways to to mitigate those things and we we educate patients and and care for them along the way to help mitigate those, but they usually people can get comfortable and subside over time. >> I want to ask you a question about the broader health care landscape right now. It's been kind of a newsy week for the space because OpenAI has made this new deeper push into health tech with with its new platform.

26:46 >> And one of the interesting things that we've talked about on this show is OpenAI integrating with all these different platforms, not just in healthcare, but you know, other apps and and and tools as well. But the broader question I have for you is so open AAI is going to make sense of all this data with chatbt and you know maybe you can link up your my fitness pal or maybe your Apple health at some point and you the business question that I have in my mind is isn't there a risk that these companies integrating with chatbt could just end up cannibalizing their own business and the value proposition that they had in the first place. How do you think about that issue? Well, if from our perspective, I think one of the So, first I think it's a great launch. It's exciting. I think that healthcare the established health care system I think over the last 20 25 years has had its chance to use technology and clearly has come up short for a lot of people. and I think this is just a preview of of things to come.

27:41 So, it is really exciting. I think for us the the thing that we really see about AI and it not only using it internally a bunch but when you see right now in chatbt oftentimes it'll caveat or other AI LLM you'll see it'll caveat and say and says this is not meant to replace your provider and so what we really think about is okay all of that data how do we make it actionable and at some point in time right we want to make that data actionable I mean that might be a prescription that might be provider guidance whatever it may be For us, we actually just think that the more patients are engaged with their health, the more that they can turn that unstructured into structured data and get feedback in real time, the better off they'll be. I think an interesting analogy here for Silicon Valley that's, you know, obsessed with what is the how does AI really spread throughout healthcare? I think driverless cars are actually a really good analogy here, right? and the reason I say that is you have some pockets where you'll see these very controlled experiments where they'll be fully autonomous, right? So that's like a a Whimo driving around Pal outdoor or SF. You'll see similar things in healthcare, right? So an insulin pump is sort of the V0ero. It's deterministic, but it's it's making automated decisions, right, in in real time.

28:55 you saw in Utah this week, Utah is rolling out a pilot where refill prescriptions can actually be done entirely by AI. So these very controlled experiments and they'll roll them out over time. And then you do have the equivalent of what we've seen more in like Tesla FSD or lane assist or parking or things like that where it complements the human driver and you're going to see a lot of that as well probably spread far faster. The the interesting thing to me is the society's perspective is we have this massive supply chain shortage in healthcare right too many people need it too few to provide it. That's hopefully what AI does. The societal question I think we're we're we're gonna we're facing it with driverless cars is basically like how much it's an odd way to say it like how much debt are we willing to tolerate in the interim because driverless cars in many ways we don't hold the bar that they need to be better than the average driver or even the best driver. We we hold the bar that they need to be 10x better. and I think we're probably going to do the same with healthcare. So it'll be interesting to see how it rolls out. But I think that's a good analogy for people. So, let let me ask you another question there on that societal sort of piece of all this, which is that we had a doctor on this show earlier this week talking about the question who is accountable in the scenario where somebody goes to >> an AI platform for health advice and unfortunately something goes wrong.

30:19 you know there is a question about is it the platform you know was it was there a doctor at all in the loop? How do you think about that question at row? >> So for us the the way that we think about it is for things like that the doctor will be in in in the loop right and I think there's very very clear there's very very clear regulatory guidelines in the practice of medicine and I'll give an example of where we use AI to give our providers leverage while dramatically improving the patient experience. So right now patients can report a side effect and they could do that historically in a structured way.

30:53 So what side effect they're experiencing, the severity, the duration, any other associated side effects, whether they can still move throughout their day or take the medication, and that would create a task for a provider to review. And 24/7, our our side effect response time was under an hour. Then with the launch of these LLMs, every single we could take tremendously unstructured data and make it structured. So if you're talking to Row and you send a message, every message is routed to an LLM. We can actually flag whether a side effect is reported in that unstructured message.

31:26 Create a task routed to a provider and we've published this data. We've been able to reduce the speed with which a provider can respond to a side effect by 70%. So 247 the median response time to a side effect on row is 15 minutes. That was impossible to do before LLMs. Right. >> So, I think it's it's it's going and and I that's where I think again the driverless cars are a good analogy because I think it's more familiar to people, but there's an entire spectrum of of autonomous. There's multiple levels how involved the human driver is, whether there's a test controlled pilot or highways or or all of these different smaller pockets and use cases. So, I think that's a good analogy, but that's how that's how we think about it. The last thing I want to ask you about before you go is this conversation around peptides is like everywhere now.

32:10 You know, every everyone is talking about >> peptides and micro doing right. That's a big >> peptides micro doing the look the idea of getting drugs or medications directly from a manufacturer. I don't know. I I would never do it and and I'm surprised if people do, but we are in this Silicon Valley era of people trying new things. How how do you think about moonshot bets at Rorow and what do you have your eye on in terms of innovations that are coming down the line?

32:37 >> Yeah, so there is this large as you said there's this large peptide craze. I think the you know it's it's a very high level like generic term because I think the most popular peptide will be GLP1 like >> right I was just going to say I mean that that is literally a peptide. >> It's literally a peptide. You know insulin is a peptide. we've been treating, you know, hundreds of millions of people have been taking peptides for the last basically centuries since insulin was invented about 100 years ago. So, it's not a new concept. I think this the same just needs to be applied, the same logic that we would apply would would apply to this. I think what you're seeing with people taking more action and how I take this peptide craze or this micro doing craze and by the way, I think micro dosing I have an issue with the term which I'm happy to talk about which I think it's like next time we can do it. But but I I I think that you're just what you are seeing it's a signal of how fed up people are with the traditional system right they're taking more into their hands co I think we lost a lot of trust in institutions and you're seeing that I think this is just one other example of that and but I do think that the traditional system to your point with manufacturers they are investing more in direct to consumer and empowering patients and I think the companies that win in the future are the ones that lean into that and lean into empowering the patient and the provider to collabor to achieve their goals.

33:53 >> Great. Well, Zack, I want to thank you for coming on. We appreciate it. And next time you come on, we will have you give us your hot takes on microing. I'm sure that'll be >> that is Zach Ray Tom, co-founder and CEO of Row here on TIT. >> Okay, for this week's editor's cut, we want to take a look at the AI and the shopping story. E-commerce has become one of the biggest applications for AI that many companies are trying to expand into. I want to bring on our editors Martin Piers and Meredith Misili to talk about some of the dynamics at play right now. Welcome to you both. It's great to have you here.

34:28 >> How are you? >> Hey guys. >> I'm doing well. And just to set the scene here for people, Meredith and Martin sit next to each other. Okay. So, I'm expecting a dynamic lively conversation >> in the office at home. I'm in the office. >> In the office, right, got it. >> Not collaborating. Yeah. >> Yeah. >> There's no collaboration. has just gotten out of her pajamas and she whereas I'm here in the office. >> All right. Well, let's let's just talk about e-commerce. How about that? So, I'm going to put a prediction ahead and I want your thoughts on this, which is that I actually think that Amazon is going to make a lot of noise this year in the AI e-commerce story. I think they're going to push ahead in some cases and I think this is going to be the year that Amazon finally breaks out.

35:18 I think shopping is going to be at the center of that. Meredith, what do you think of that prediction? >> Hey, thanks Akash. So, I largely agree with your position there. I have a couple asterisks, but I will get into that. So, first of all, off the bat, agree. Amazon is already obviously a massive destination for online shoppers. It's a place where people go where they expect to shop. I don't know that that's the same of Chat, GPT, Copilot, everybody else that's trying to roll out these shopping tools. and user habituation right now is a big question.

35:50 Will people actually use AI to shop? And I think Amazon has a big leg up there. and more importantly, we're seeing this week especially evidence that Amazon is getting its AI agents or what they call agents to actually shop online, which I can get into that later, but it's a lot harder than it might sound. and the reason we know that they're doing this is that small retailers started to get pissed off about it. Am I allowed to say that on this show?

36:18 >> You are. You are very much allowed to say it >> because this week we saw a bunch of little retailers that don't sell on Amazon. they don't like slashprobably hate Amazon saying, "Hey, like we're seeing our stuff show up through this agentic tool and we're getting sales via Amazon and we don't like that." So, in a weird way, the fact that other retailers are starting to notice and they're getting ticked off, that is showing that Amazon's AI tools are actually working, which at this stage of the game, just having something work, even if it's not perfect, is being ahead.

36:52 Okay. So, Martin Meredith thinks she agrees with me actually think this is this is going to be the year. What do you think? >> Well, I mean I think that's like saying that I don't know. I mean that doesn't mean very much to me. Amazon has been very quiet on the AI front. So, it wouldn't be hard for them to make more noise this year and I agree that they will, but I don't I just don't think that that means much. Look, I'm very confident that Amazon will in the end do very well in AI as far as it needs to.

37:22 It it doesn't need to spend the money that some of the other companies are spending. you know, they just need to spend the money to ensure that their cloud service has the capacity to meet demand and to ensure that the AI products for Amazon.com work. and I'm sure that they will actually do that, but you know, I don't think that they're going to make a whole lot of noise, anything like what Google has done or, open AI.

37:55 >> Yeah, sure. But I mean, I think the AI component of AI shopping as we're thinking of it now is very small compared to the retail component. And that's where Amazon's really good. And you know, we covered this with OpenAI this week where there's this recurring problem with AI shopping agents where they just get tripped up by product data, by little details that you might not think about like sales tax in different states, stuff like that, and then they just don't work. So like what OpenAI is trying to do is team up directly which has very little to do with AI just kind of plug in directly with retailers with payments firms with this AI layer over it. Like yes Amazon's AI is probably like less good in that sense but the underlying commerce part they I think they still have an advantage there. A cash, you didn't tell me that we're having an Amazon spokesperson come this was a editor's >> This is this is my caveat though and I'm I'm circling back to this from the beginning. All the hype around AI agents is this idea that okay, we're going to have this like personal shopper like tool that goes out there, it buys your stuff, it makes an outfit for you, it picks something out for your dad that's like impossible to shop for and never likes what you get him.

39:11 >> are you are this is like a personal issue for you? Yeah, no, no, no. I just But so this but that we are so far from that we are not even close. the the way that AI agents are working now is within very set boundaries and in very specific situations and that that is why Amazon is doing okay. And like I think if somebody can figure out how to make that bigger picture thing, this like ideal a reality there's like that that is a huge blank open space for sure that you know like I to agree with Martin I hate to say or at least like somewhat go on his side like that is not something that Amazon's doing yet. Martin, we had Katherine Pearllof on the show earlier this week talking about her reporting and I was talking to her about some of the core reasons that Amazon may have fallen behind in the AI conversation at least from a a narrative point of view.

40:06 And look, she mentioned that Google had some very early efforts in AI and Microsoft obviously had its open AI investment. Amazon, you know, there was no sort of clear early project that really may have given it a head start. do you agree with that being a core reason? Are there other reasons you think are at play? >> No, I I think that that is the main reason. Google, Meta, Microsoft, all of them had been in AI for years. Amazon wasn't I'm not sure as I said that Amazon needs to compete with those other companies in that same way that they need to do AI as it serves their needs and I think that they've taken a very smart approach to not try to compete with the others. Meredith, you pointed this out this morning that this week Microsoft also said that it was going deeper into e-commerce and shopping. They they did and they announced something that is quite similar to the open AI checkout. So just to zero zoom out a little bit what that means is inside co-pilot inside chat GBT these companies say you will soon be able to buy a lot of different stuff without leaving the window. and they say that's a really big deal because every time a shopper leaves the window has to go to another website you lose a few shoppers along the way. So, I'm going to use some jargon that Martin will hate, but the shopper conversion within the >> they convert to >> how do they convert? What's the conversion?

41:39 >> Better yeah, is better is what they say. But, again, like this that approach is just not really working yet. It's working on a very limited basis. and then what Amazon's trying to do is much more like go out to the web again, not really AI, like scraping stuff. basically sounds like a bot, right? and then finding stuff and bringing it back. >> I mean, a case, you have to remember we're in the period right now where companies are are announcing things constantly. Many of these announcements, you know, will never work and we'll never hear anything of them. But the media being what it is, they write them up as though they're really important.

42:16 so we have to treat everything, you know, skeptically. >> Yeah. And just like agreeing with Martin again, I don't know how this keeps happening, but I would >> It's because I'm smart. I will point out that the initial open AI announcement around these checkouts came I believe in September. So before Black Friday, Cyber Monday, like the Super Bowl of retailers each year. that came and went and these checkouts weren't really scaled up. So it, you know, it's not going to be until the next key shopping period at the earliest that we're really going to see this potentially be positioned to take off. And I think we were hearing in the reporting that a lot of retailers anyway don't like making big changes before the holiday season. So the timing of that was interesting that it came out and you know >> and look the other thing is that people liked to buy things. So I'm not sure that they really want to turn over that that that you know behavior to some agent they like.

43:14 >> Well that's that's actually a good point that yeah I mean I hadn't thought about that. I mean having agency over the thing that you buy is in and of itself a very >> people enjoy the experience mostly. >> Right. >> Right. >> Not everybody but >> Right. Okay. Well, I'll tell you what that's a good place to end it. I want to thank you both for coming on. That is Martin and Meredith. Two of our most fun editors here at the information for this week. Not >> very high editors cut. Okay. All right.

43:41 Okay. You know what? We're get out of here. I'll talk to you guys. Talk to you guys very soon. >> >> All right. for where are we in the show here though? Okay. Many health tech companies now are starting to offer products and services now that will tell you your biological age. My colleague Jamaima Makavoy wrote a deep dive in our weekend magazine about that trend and about some of the complexities that come up with companies offering these new features. I want to bring her on to talk all about it. Jamaima, welcome back to the show. It's great to have you here.

44:12 >> Hi Aash. It's great to be here. I should preface this by saying we look, we've talked a lot about health tech on the show so far today. We've talked about GLP1s, we've talked about peptides, we almost talked about micro doing. We didn't quite get there. And so biological age is right on the money for the realm of things that I want to get to. Did you track your biological age as part of this story that you wrote? I really wanted to, but because of the timeline with the story, we were worried that the results wouldn't come back in time. So, yeah, cuz this is different than like, you know, looking at your your watch.

44:50 >> This is not like like telling me like, oh, my whoop tells me I'm, you know, younger. >> No, no, no. So, that's different there. There's like lots of different types of biological age tests and and those are more just like measures. They're a little more casual. The ones that I'm talking about in these stories are the kits that you order to your house. You take like a cheap a cheek swab or like a blood sample, >> send it off to a lab, and then a few weeks later they'll send you back your your score based on like a variety of different measurements. interestingly though, like one founder that I spoke to who who runs one of the companies that sells biological age tests, he told me that he thinks that the best way to measure biological age might be by just looking at your face. and you know guessing your age based on >> shocker waking up in the morning looking in the mirror.

45:39 >> Yes. And he said that my age was the what what it actually was. He just guessed it. So anyway, I don't know what it says about my physiology. >> Is do we do that? We just look people and guess their age. I mean is that something we do >> in this world? Yes. >> I guess so. Okay. Well, look, I I liked your story a lot because it dived into the way that Silicon Valley has embraced it. not just from an adoption perspective, but also from a business perspective. Talk a little bit about who the big companies are, how much money is going into this space, and then really what some of the complexities are around being able to say that you are 30 years old, but you're actually 25 or you're actually 35.

46:20 >> Yeah. So, there's I by my count there's 15 different companies that are selling biological age tests. They're all I mean a lot of them are different versions which I'll get into in a second. But also by my account they've these companies have raised around $800 million. It's worth noting though that a lot of these companies do sell other stuff like supplements, longevity related things like other health testing kits that aren't focused on biological age but they offer these tests too.

46:48 and so the complexities is that well there's one big one which is that I spoke to a bunch of scientists in the space and they all agree including some of the scientists who developed the technology that are used in some of these commercially available clocks and they all agree that you can't definitively say that we can measure biological age because there's no definition. It's not like height or weight where we all agree like you measure height and weight in a specific way. Biological age there's no consensus. So, it's confusing to consumers. You're going to get different scores depending on the test that you choose to do because they're a lot of them are measuring different things >> right now. What do the companies say about this? What's their what's their rebuttal?

47:33 >> Yeah, a lot of them argue that it's useful to track over the long term. are tracking trends. when I >> relatively speaking, I mean, you know, even if you're not the same as what the other company says, if you're getting younger, it's better. >> Exactly. So, like test yourself every six months, watch how that changes. You know, the problem is in in a lot of these companies marketing, it's a lot more definitive. Like, we're going to tell you your biological age. This is how healthy you are. In some cases, arguing this is like the best way to look at how your body is doing internally. so there's kind of this difference between how these how these companies are marketing what they can do versus what they can actually do.

48:14 also the experts I spoke with were divided on whether there's actually any value on tracking over time either. you know, if the tests aren't particularly accurate in the first place, why would it be valuable to check over time? Also, and then just one more point I want to mention is that I'm not trying to say that biological clocks are completely useless. They've been used in aging studies and continue to be used in research a lot. the problem is that they have been started to be sell sold commercially without really checking how useful they are on an individual level and how accurate they are on an individual level. So there's kind of this difference between being able to measure like changes in populations versus testing how effective they are for individuals.

48:58 Was there a particular story that you heard over the course of your reporting that really just shocked you about the lengths that people will go to? Maybe not just to measure their biological age, but look, we've been talking all day today about the crazy things people are trying to get information about their bodies and about how they can improve. I mean, is there is there a story that stands out to you that you were just flabbergasted about? Yeah, I mean I I do think that this is a small subset of people that are really on the extreme end of this, but among those people, there are a lot of great stories. I mean, one founder I was speaking with, he told me, and this is in my story, but one of his friends texted him after getting her results back from a biological age test she did, and she showed up as being 10 years older than she is in reality. And she was just begging him over text like, "What can I do to change this? I'll I'll pay you $10,000. You know, that may have been an exaggeration and perhaps >> $1,000 for every year. I mean, that's the going rate, I guess.

50:03 >> Seems reasonable, but I mean, there are a lot of people in Silicon Valley who really care and are hoping that we can reverse aging and think it's on the horizon. So, I yeah, I don't think this is going to go away. >> And last question for you. Do you think Well, actually, you just answered. I was going to say, is this a fad? Is it going to go away? So, you think this is here to stay? Yeah, this is definitely here to say and you know the scientists in the space keep saying that there are you know big breakthroughs coming and and there's a lot of hope that there's going to be breakthroughs in the industry and and investors just seem to be willing to throw a lot of money at it even though you know we haven't seen any massive massive breakthroughs yet. so yeah I I don't think it's going to go away.

50:44 Interest is going to stay. >> Great. Well Jamaima I want to thank you for coming on. And that is Jamaima Makavoy, our weekend reporter here at the information. Okay, that does it for today's show. A reminder, we are on this stream Monday through Friday at 10 a.m. Pacific, 1 p.m. Eastern. I want to thank you all for tuning in. We really do appreciate your viewership. I'm already excited for our next show tomorrow. not tomorrow, today's Friday. I'll see you on Monday. Have a great weekend.

51:11 Talk to you soon. Bye-bye for now.

Summary

DeepS is set to launch its new AI model, V4, which reportedly outperforms competitors in coding capabilities. Additionally, Straa has confidentially filed for an IPO, while Lambda, backed by Nvidia, is seeking to raise $350 million ahead of its own IPO. The show features discussions on AI's impact on media, health tech innovations, and the growing trend of biological age assessments.

- DeepS will release its V4 AI model soon, boasting enhanced coding capabilities.
- Straa has filed for an IPO, with significant revenue growth projected.
- Lambda is in talks to raise $350 million before its IPO, highlighting the demand for cloud services in AI.
- Dan Shipper from Every discusses the integration of AI in media and productivity tools.
- Zack Rayano from Row introduces a new GLP1 pill, emphasizing its affordability and efficacy compared to injectables.
- The health tech landscape is evolving with AI, raising questions about accountability and patient engagement.
- The trend of biological age testing is growing, with significant investment but concerns over accuracy and marketing practices.
- The conversation reflects a broader societal interest in health optimization and the role of technology in personal health management.

Questions Answered

What are the key topics and guests for today's show?

The show will cover the upcoming launch of DeepS's new AI model, an IPO filing by Straa, and Lambda's fundraising efforts. Guests include Dan Shipper from EveryY and Zach Rayano from Row.

What is the current status of M&A discussions and Lambda's IPO?

There are no explicit M&A conversations, but larger companies may consider acquiring smaller firms like Lambda, which is trying to raise $350 million before going public.

How is AI changing the way we interact with technology?

AI is extending its capabilities beyond coding, allowing for more valuable interactions, such as automating routine tasks in web settings.

How are LLMs improving patient response times for side effects?

LLMs are enabling faster and more efficient processing of unstructured data related to patient side effects, reducing response times significantly.

What are the implications of new e-commerce features announced by companies?

Companies are introducing new features for in-window shopping, but skepticism remains about their effectiveness and scalability.

© transcribe · For agents Built with care and craft by Gokul Rajaram